摘要
目的:研究杨梅素(myricetin,YMS)抗离体心脏心肌缺血再灌注损伤作用。方法:将实验分为正常组、模型组、YMS组与YMS+GW9662(PPARγ的选择性阻断剂)组。采用Langendorff造模方法,利用生物多导记录仪连续测定血流动力学参数,TTC染色法检测心脏梗死面积。ELISA法检测白介素6(IL-6)、C反应蛋白(CRP)和肿瘤坏死因子α(TNF-α)的含量。通过Western blot方法检测心肌组织中过氧化物酶增殖物激活受体γ(PPARγ)和NF-κB的蛋白表达。结果:与正常组相比较,模型组出现严重的心脏功能障碍和较大的心肌梗死面积,心肌组织中CRP,IL-6和TNF-α含量增加,心肌组织中NF-κB的蛋白表达量显著升高。与模型组对比,YMS组的心脏功能显著恢复,心肌梗死面积明显降低;心肌组织中CRP,IL-6和TNF-α含量显著降低,YMS组PPARγ的表达量显著升高,而NF-κB的表达量显著降低。YMS的这种心脏保护作用几乎全部被GW9662阻断。结论:YMS具有显著的抗心肌缺血再灌注损伤作用,其机制可能与PPARγ/NF-κB信号通路有关。
Objective： To evaluate the cardioprotective effects of myricetin（ YMS） on ischemia/reperfusion（ I/R） injury using an isolated Langendorff rat heart model and study the possible mechanism of YMS against I/R injury. Methods： Using the Langendorff modeling method,the experiment was divided into normal group,model group,YMS group and YMS ＋ GW9662（ PPARγ selective blocker） group. The left ventricular developed pressure（ LVDP）,coronary flow（ CF） and the maximum up/down rate of the left ventricular pressure（ dp/dt（max）） were documented as the indices of myocardial function by a physiological recorder. Myocardial infarct size was macroscopically estimated using 2,3,5-triphenyltetrazolium chloride（ TTC） staining. The levels of interleukin-6（ IL-6）,C-reactive protein（ CRP） and tumor necrosis factor-α（ TNF-α） were measured by ELISA. The proteins levels of peroxisome proliferators-activated receptor gamma（ PPARγ） and nuclear factor-k-gene binding（ NF-κB）were measured by Western blot. Results： Pretreatment with YMS improved the maximum up/down rate of the left ventricular pressure（ dp/dt（max））,raised the LVDP,improved CF,reduced the amount of CRP,IL-6 and TNF-α,upregulated PPARγ expression,and downregulated NF-κB expression. However,the effects of YMS were reversible by co-treatment with PPAR-γ inhibitors（ GW9662）. Conclusion： I/R injury in rat hearts can be prevented by pretreating with YMS which modulates PPARγ activation-dependent NF-κB signaling pathways.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2017年第12期1455-1460,共6页
Chinese Journal of New Drugs
基金
滨州医学院科研启动基金资助项目(BY2014KYQD01)
新疆生产建设兵团重点领域创新团队资助项目(2015BD005)
山东省高等学校优势学科人才团队培育计划资助项目(鲁教2016052410)
